What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?

P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

(2023) Paolo F Caimi et al.   HemaSphere

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers

(2022) Francesca Zammarchi et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer

(2022) Stephen J. Gregson et al.   MOLECULAR CANCER THERAPEUTICS

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

(2022) Nitin Jain et al.   BLOOD

Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

(2021) Johann S. de Bono et al.   CLINICAL CANCER RESEARCH

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

(2021) Paolo F Caimi et al.   LANCET ONCOLOGY

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

(2021) Mehdi Hamadani et al.   Lancet Haematology

Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy

(2020) John A. Hartley   EXPERT OPINION ON BIOLOGICAL THERAPY

Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study

(2020) Aaron D. Goldberg et al.   LEUKEMIA RESEARCH

Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

(2020) Mehdi Hamadani et al.   BLOOD

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

(2018) Amir T. Fathi et al.   BLOOD

Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine

(2018) John A. Hartley et al.   Scientific Reports